On Invalid Date, Matinas Biopharma Holdings (NYSEMKT: MTNB) reported Q4 2023 earnings per share (EPS) of -$0.03, up 50% year over year. Total Matinas Biopharma Holdings earnings for the quarter were -$5.31 million. In the same quarter last year, Matinas Biopharma Holdings's earnings per share (EPS) was -$0.02.
As of Q2 2024, Matinas Biopharma Holdings's earnings has grown year over year. Matinas Biopharma Holdings's earnings in the past year totalled -$22.94 million.
What is MTNB's earnings date?
Matinas Biopharma Holdings's earnings date is Invalid Date. Add MTNB to your watchlist to be reminded of MTNB's next earnings announcement.
What was MTNB's revenue last quarter?
On Invalid Date, Matinas Biopharma Holdings (NYSEMKT: MTNB) reported Q4 2023 revenue of $0.00 up 100% year over year. In the same quarter last year, Matinas Biopharma Holdings's revenue was $1.06 million.
What was MTNB's revenue growth in the past year?
As of Q2 2024, Matinas Biopharma Holdings's revenue has grown -65.62% year over year. This is 209.61 percentage points lower than the US Biotechnology industry revenue growth rate of 143.99%. Matinas Biopharma Holdings's revenue in the past year totalled $1.10 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.